Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonapanitase - Proteon Therapeutics

Drug Profile

Vonapanitase - Proteon Therapeutics

Alternative Names: PRT 201; Recombinant-human-type-I-pancreatic-elastase

Latest Information Update: 30 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteon Therapeutics
  • Class Elastases; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Extracellular matrix protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vascular disorders
  • Phase I Peripheral arterial disorders

Most Recent Events

  • 24 Jan 2019 Proteon plans to file a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for Vascular disorders in the first half of 2020
  • 07 Nov 2018 Proteon Therapeutics initiates a phase I trial in Peripheral arterial disorders in USA (Intra-arterial, Injection)
  • 08 May 2018 Proteon Therapeutics announces intention to submit BLA to US FDA for Vascular disorders in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top